Ultimovacs ASA (OSL:ULTI) Institutional Ownership : 5.67% (As of Jun. 09, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ultimovacs ASA's institutional ownership is 5.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ultimovacs ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ultimovacs ASA's Float Percentage Of Total Shares Outstanding is 0.00%.

Ultimovacs ASA Institutional Ownership Historical Data

The historical data trend for Ultimovacs ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Institutional Ownership Chart

Ultimovacs ASA Historical Data

The historical data trend for Ultimovacs ASA can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	8.77	8.77	8.23	8.42	8.86	8.66	7.82	6.34	5.63	5.67

Ultimovacs ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.